UK-based GlucoRx are joining the UK Pavilion at MEDICA 2022 to showcase the world’s first multi-sensor non-invasive continuous glucose monitor (CGM), heralding a new era of needle-free monitoring for people with diabetes.
The GlucoRx BioXensor™ uses patented radio frequency technology alongside a multiple sensor approach to measure blood glucose levels every minute reliably, accurately, and non-invasively.
According to the World Health Organization, approximately 422 million people around the globe have diabetes. Currently, many patients have to prick their finger to extract and test their blood several times a day using glucometers, or apply semi-invasive devices such as continuous blood glucose monitors (CGMs).
The GlucoRx BioXensor™ now provides an alternative to blood glucose monitoring for the first time by measuring levels from 3 mmol/l to 30 mmol/l. When used as an early intervention to change lifestyle, the GlucoRx BioXensor™ can assist in preventing the onset of diabetes, or its remission, and improve quality of life with its smart alarms and remote monitoring technology.
Chris Chapman, GlucoRx Chief Operating Officer, said: “We are excited about this life-changing end-to-end diabetes monitoring platform of ours which can be discreetly stuck on the skin to monitor blood glucose, giving readings every minute on smart mobile applications, and look forward to showcasing our ground-breaking technology at this year’s Medica trade fair.
“GlucoRx BioXensor™ has standout accuracy owing to its multi sensor approach capturing blood glucose as well as Sp02, ECG, respiration rate, heart rate, temperature, activity, sleep, and early fall detection. The wearable device has a longer shelf-life because it is not chemical in its action.”
This work was supported by the Wellcome Trust and Cardiff University through its Cardiff Partnership Fund. Dr Heungjae Choi was funded by the Sêr Cymru II Fellowship by the European Regional Development Fund through the Welsh government.
Following a series of successful trials on early generation prototypes which achieved MARD of 10.4% at Swansea University with Professor Stephen Luzio, the team is now said to conduct a further pivotal clinical study later this year on its smaller and improved fourth generation device before submitting CE certification.
Founded in 2011, GlucoRx is one of the UK’s leading suppliers of medical products and platforms to improve the wellbeing of all people with diabetes. The company is empowering users and their caregivers with comprehensive AI driven data ecosystem for effective diabetes control, enabling best treatment decisions to live a fulfilling life.
GlucoRx was also the first company to roll out real-time continuous glucose monitors (CGMs) to NHS patients with type 1 diabetes with 14 days use. The GlucoRx AiDEX™ CGM has been available on the Drug tariff since April 1, 2022.
MEDICA is taking place from 14 - 17th November 2022 and throughout the show, GlucoRx will be located on the ABHI UK Pavilion – Hall 16 stand K48.
For more information about GlucoRx, visit https://www.glucorx.co.uk/
https://bioxensor.com/ or email info@BioXensor.com
